|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Other
Biopharmaceuticals Products
Azactam revenue decreased by 27% to $37.7 million in
the first half of 2009 from $51.9 million in the first half
of 2008. The decrease was principally due to supply shortages.
Azactam lost its patent exclusivity in October 2005 and
its future sales are expected to be negatively impacted by
generic competition. However, no generic form of Azactam
has been approved to date. Our sole source for Azactam
has indicated they will cease the supply of product to us
beyond 2009. We are in discussions with this supplier with
respect to its obligations to supply. However, if we are unable
to resolve these differences with our supplier or are unable to
obtain an alternative source of supply, our sales of Azactam
will rapidly decrease.
Prialt revenue increased 10% to $8.7 million in the
first half of 2009 from $7.9 million in the first half of
2008. The increase was primarily due to higher demand for the
product.
Maxipime revenue decreased 58% to $7.6 million in
the first half of 2009 from $18.3 million in the first half
of 2008. The decrease was principally due to the introduction of
generic competition. The first generic cefepime hydrochloride
was launched in June 2007, and additional generic forms of
Maxipime have since been launched. We expect that the
generic competition will continue to materially and adversely
affect our revenues from, and gross margin for, Maxipime.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Other
Biopharmaceuticals Products
Azactam revenue increased 12% to $96.9 million in
2008 from our 2007 sales level of $86.3 million, mainly
reflecting increased pricing. Azactam lost its patent
exclusivity in October 2005, and its future sales are expected
to be negatively impacted by generic competition, although to
date no generic form of Azactam has been approved.
Maxipime revenue decreased 78% to $27.1 million in
2008 from our 2007 sales level of $122.5 million. The
decrease was principally due to the introduction of generic
competition. In June 2007, the first generic formulation of
cefepime hydrochloride was approved by the FDA. Generic cefepime
hydrochloride was launched shortly thereafter, and additional
generic forms of Maxipime have since been launched. We
expect generic competition to continue to materially and
adversely affect our revenues from, and gross margin for,
Maxipime.
Prialt revenue increased 34% to $16.5 million in
2008 from our 2007 sales level of $12.3 million. The
increase was primarily due to higher demand for the product.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Other
Biopharmaceuticals products
Azactam revenue increased 12% to $96.9 million in
2008 from our 2007 sales level and increased 11% to
$86.3 million in 2007 from our 2006 sales level, mainly
reflecting increased pricing. Azactam lost its patent
exclusivity in October 2005, and its future sales are expected
to be negatively impacted by generic competition, although to
date no generic form of Azactam has been approved.
Maxipime revenue decreased 78% to $27.1 million in
2008 from our 2007 sales level and decreased 23% to
$122.5 million in 2007 from our 2006 sales level. The
decreases in 2008 and 2007 were principally due to the
introduction of generic competition. In June 2007, the first
generic formulation of cefepime hydrochloride was approved by
the FDA. Generic cefepime hydrochloride was launched shortly
thereafter, and additional generic forms of Maxipime have
since been launched. We expect generic competition to continue
to materially and adversely affect our revenues from, and gross
margin for, Maxipime.
Prialt revenue increased 34% to $16.5 million in
2008 from our 2007 sales level and increased 2% to
$12.3 million in 2007 from our 2006 sales level. The
increases in both 2008 and 2007 were primarily due to higher
Table of Contents
demand for the product. Prialt was launched in the
U.S. market in the first quarter of 2005. In March 2006,
we completed the sale of the European rights to Prialt
to Eisai, while retaining the product rights in the United
States. We had not made any commercial sales of Prialt in
Europe prior to the divestment.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
